2022 | Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy | Wang, Eunice S; Montesinos, Pau; Minden, Mark D; Lee, Je-Hwan; Heuser, Michael; Naoe, Tomoki; WEN-CHIEN CHOU ; Laribi, Kamel; Esteve, Jordi; Altman, Jessica K; Havelange, Violaine; Watson, Anne-Marie; Gambacorti-Passerini, Carlo; Patkowska, Elzbieta; Liu, Shufang; Wu, Ruishan; Philipose, Nisha; Hill, Jason E; Gill, Stanley C; Rich, Elizabeth Shima; Tiu, Ramon V | Blood | 51 | 35 | |